Robert Christopher Andrade Purchases 15,816 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88.

Fennec Pharmaceuticals Stock Down 0.5 %

TSE:FRX traded down C$0.03 during trading hours on Thursday, hitting C$6.47. The stock had a trading volume of 2,037 shares, compared to its average volume of 1,869. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.43. The business has a 50 day simple moving average of C$6.40 and a two-hundred day simple moving average of C$7.99. The company has a market cap of C$177.02 million, a PE ratio of 65.00 and a beta of 0.25.

Analysts Set New Price Targets

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.